Horseshoe thrombus in a patient with mechanical prosthetic mitral valve: A case report and review of literature

Sanjay Mehra, Assad Movahed, Carlos Espinoza, Constantin B Marcu

Sanjay Mehra, Assad Movahed, Carlos Espinoza, Constantin B Marcu, Department of Cardiovascular Sciences, East Carolina University, Greenville, NC 27834, United States

Author contributions: Mehra S and Marcu CB designed the research and identified the case reported; Mehra S and Espinoza C performed review of literature; Mehra S prepared manuscript; Movahed A and Marcu CB revised manuscript.

Conflict-of-interest statement: The Authors have no conflict of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Assad Movahed, MD, FACC, FACP, Department of Cardiovascular Sciences, East Carolina University, 115 Heart Drive, Greenville, NC 27834, United States. movaheda@ecu.edu Telephone: +1-252-7444400

Received: March 23, 2015
Peer-review started: March 25, 2015
First decision: April 10, 2015
Revised: April 21, 2015
Accepted: June 4, 2015
Article in press: June 8, 2015
Published online: September 16, 2015

Abstract

Patients with prosthetic cardiac valves are at high risk for thromboembolic complications and need lifelong anticoagulation with warfarin, which can be associated with variable dose requirements and fluctuating levels of systemic anticoagulation and may predispose to thromboembolic and or hemorrhagic complications. Prosthetic cardiac valve thrombosis is associated with high morbidity and mortality. A high index of suspicion is essential for prompt diagnosis. Transthoracic echocardiography, and if required transesophageal echocardiography are the main diagnostic imaging modalities. Medically stable patients can be managed with thrombolytic therapy and anticoagulation, while some patients may require surgical thrombectomy or valve replacement. We present a case report of a patient with prosthetic mitral valve and an unusually large left atrial thrombus with both thromboembolic and hemorrhagic complications.

Key words: Thrombosis; Anticoagulation; Thrombolytic therapy; Transthoracic echocardiogram; Prosthetic valves; Transesophageal echocardiogram

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Patients with mechanical prosthetic cardiac valves require lifelong systemic anticoagulation. Maintaining therapeutic anticoagulation consistently is challenging, given the variable dose requirements with warfarin, especially with dietary changes and drug interactions. We present a case of a patient with fluctuating control of anticoagulation, which led to an unusually large horseshoe thrombus in her left atrium and subsequent cerebrovascular complications. We also provide a review of literature, diagnostic modalities and treatment options.

Mehra S, Movahed A, Espinoza C, Marcu CB. Horseshoe thrombus in a patient with mechanical prosthetic mitral valve: A case report and review of literature. World J Clin Cases 2015; 3(9): 838-842. Available from: URL: http://www.wjgnet.com/2307-8960/full/v3/i9/838.htm DOI: http://dx.doi.org/10.12998/wjcc.v3.i9.838
INTRODUCTION

Patients with prosthetic cardiac valves are at high risk for thromboembolic complications and need lifelong anticoagulation with warfarin. Thrombosis of a mechanical prosthetic cardiac valve is a serious complication with high morbidity and mortality. Advances in valve design and surgical techniques have improved prognosis but thromboembolism remains a source of complications in patients with mechanical prosthetic cardiac valves. Warfarin is the only oral anticoagulant approved for systemic anticoagulation in patients with prosthetic cardiac valves. However, warfarin has been associated with variable dose requirements related to common genetic polymorphisms influencing their metabolism, varying amounts of dietary intake of vitamin K and interactions with other drugs being used concomitantly. Fluctuating level of systemic anticoagulation may predispose to thromboembolic and or hemorrhagic complications. We present a case of a patient with a mechanical bi-leaflet mitral valve prosthesis who presented to our institution with an unusually shaped and large sized left atrial thrombus. The case exemplifies a recognized complication in this patient population and is followed by a review of literature including pathogenesis, clinical presentation and treatment options.

CASE REPORT

A 77-year-old female with medical history of severe rheumatic mitral stenosis treated with mitral valve replacement with 31 mm St. Jude mechanical bileaflet valve was brought to our emergency room with acute onset of right sided weakness and altered mental status by emergency medical services (EMS). Per a family member patient had complained of not feeling well and while EMS was being contacted, she became unresponsive. EMS intubated the patient for airway protection. Upon arrival to our hospital the patient was unresponsive, with heart rate of 127/min, irregular rhythm, blood pressure of 127/55 mmHg and temperature of 36.6 degrees centigrade. On chest auscultation heart sounds were soft with no clear audible valve click. Bilateral lung air entry was decreased with scattered crepitations. Neurological examination revealed pupils reactive to light but deviated to the left and right arm and leg paralysis. The patient was admitted to the medical intensive care unit. Review of her medical record showed that she had labile control of systemic anticoagulation with warfarin, with international normalized ratio (INR) fluctuating between 1.4 to 3.5 in the past six months; INR was 2.3 on admission. Initial laboratory investigations revealed leukocytosis, with white blood cells at 34.4 k/mL, hemoglobin 10.1 g/dL, platelets 845 k/mL, sodium 144 meq/L, blood urea nitrogen 23 meq/L and serum creatinine 0.7 meq/L. Electrocardiogram showed atrial fibrillation with ventricular rate of 113/min, with non-specific ST changes. Blood cultures were obtained and the patient was started on broad spectrum antibiotic coverage. Computed tomography (CT) scan of the head revealed no acute changes but old bilateral cerebellar lacunar infarcts and mild diffuse atrophy. An urgent transthoracic echocardiogram (Figure 1A) showed an oval shaped echo density (1.3 cm × 2.4 cm) attached to the atrial side of the mitral valve in a dilated left atrial cavity, likely representing a thrombus. Mean and peak pressure gradients across the mitral valve were 4 and 14 mmHg respectively (Figure 1B), which were similar to the gradients post-valve implantation. The left ventricular systolic function was mildly decreased with ejection fraction of 40%-45%.

Subsequently transesophageal echocardiogram was performed which revealed a horseshoe shaped, partially mobile, echo density, consistent with thrombus around the sewing ring of the mechanical valve on the left atrial side (Figure 2). Neurology team recommended anticoagulation with therapeutic intravenous heparin at 12 units/kg body weight per hour without initial bolus. Meanwhile patient deteriorated clinically with hypotension not responsive to fluid challenge and decreasing urine output and patient was started on pressor support. Repeat CT scan of the head showed interval development of extensive hypodensity in the left frontal, parietal, insular and temporal lobes and involving the left basal ganglia, with associated petechial hemorrhages. Heparin was subsequently discontinued due to intracerebral hemorrhage (ICH) seen on computed tomography of the head. The patient was initially anticoagulated with therapeutic intravenous heparin, which was subsequently discontinued due to ICH seen on computed tomography of the head. Thrombolytic therapy was contraindicated due to ICH. The patient passed away after withdrawal of life support per family’s wishes.

DISCUSSION

According to a meta-analysis by Cannegieter et al[6], the incidence of valve thrombosis in prosthetic heart valve recipients was 1 per 100 patient-years in patients on warfarin therapy and around four times higher in patients on no anticoagulation therapy. The incidence of thrombosis was twice as likely for prosthetic valves in the mitral position as compared to the aortic position. Caged ball valves have a higher incidence of thrombosis compared to tilting disc and bileaflet valves[6]. Lengyel[7] reported the incidence of prosthetic cardiac valve thrombosis to be between 1%-4% despite adequate anticoagulation. Prosthetic mechanical valves in the mitral or tricuspid position, first generation Ball-cage and tilting-disc mitral valves have higher incidence of thrombosis. The pathogenesis of thrombosis is likely multifactorial, depending upon the thrombogenic effect of prosthetic material, left atrial geometry and function, presence of atrial fibrillation, inadequate anticoagulation, altered transprosthetic blood flow and any other cause for hypercoagulable state such as malignancy or...
Inadequate anticoagulation could be a result of variable dose requirements of warfarin. Three new oral anticoagulants (NOACs) - dabigatran, rivaroxaban and apixaban are approved for systemic anticoagulation for patients in atrial fibrillation but not approved for patients with prosthetic cardiac valves. NOACs have several advantages over warfarin, including less dietary interference with their metabolism, fewer drug interactions and a more predictable anticoagulant effect that allows for administration of NOACs in fixed doses without the need for routine coagulation laboratory monitoring. The RE-ALIGN study evaluated the use of dabigatran in patients with mechanical heart valves. The trial was terminated early because of excess of thromboembolic and bleeding events among patients in the dabigatran group. Hence despite shortcomings, warfarin is the only oral anticoagulant approved for anticoagulation in patients with prosthetic cardiac valves for now.

Clinical features suggestive of cardio-embolic source include sudden onset of symptoms, loss of consciousness at onset, rapid regression of symptoms, simultaneous or sequential strokes in different arterial territories, or evidence of embolism to other organs. Presence of bi-hemispheric cerebrovascular, combined anterior and posterior circulation, or bilateral or multilevel posterior circulation infarcts on CT scan of the head are suggestive of cardioembolism. In our patient’s case the presentation was acute, with rapid deterioration in neurological status. Initially the head CT scan showed bilateral old infarcts, suggestive of cardioembolic source. However, the new infarcts on repeat imaging were extensive and confined to the left hemisphere.

Clinical presentation for patients with thromboembolic complications may vary from being asymptomatic to dyspnea, cardiogenic shock, cerebral or peripheral embolic episodes. Loss of prosthetic valve click on clinical examination may be suggestive of prosthetic valve thrombosis. Transthoracic echocardiogram is the initial diagnostic tool and provides information about valvular morphology and function. Transesophageal echocardiography is often required to provide more accurate images and to distinguish between pannus and thrombus. A thrombus has usually an echodensity similar to the myocardium while pannus appears more hyperechoic. Fluoroscopy may also be useful for assessment of valve function by showing restriction of valve leaflet movements in case of prosthetic valve thrombosis.

Treatment options include thrombolytic therapy, surgical thrombectomy or surgical replacement of the valve. Depending on the clinical status of the patient,
surgical mortality can be as high as 69%. Thrombolytic therapy can also result in thromboembolic complications or hemorrhage, as well as complications associated with warfarin. The authors have recommended that in all patients with confirmed right-sided prosthetic valve thrombosis initial treatment should be intravenous thrombolytic therapy, with serial echocardiograms. Thrombolytic therapy may be repeated if required and urgent surgical consultation for valve-replacement should be sought for failure of thrombus resolution. Medically stable patients can be managed with thrombolytic therapy and then continued anticoagulation.

Thrombosis of mechanical prosthetic cardiac valves is associated with high morbidity and mortality and treatment options available can also be associated with serious complications. This mandates the need for high clinical suspicion for thrombosis when a patient with a prosthetic cardiac valve presents with shortness of breath or with an embolic event.

ACKNOWLEDGMENTS
Rene Robinson-Armatta for providing assistance with acquiring echocardiographic images.

REFERENCES
1. Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 1996; 112: 708-711 [PMID: 8800159 DOI: 10.1016/S0022-5229(96)70055-7]
2. Cáceres-Lóriga FM, Pérez-López H, Santos-Gracia J, Morlans-Hernandez K. Prosthetic heart valve thrombosis: pathogenesis, diagnosis and management. Int J Cardiol 2006; 110: 1-6 [PMID: 16038994 DOI: 10.1016/j.ijcard.2005.06.051]
3. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomeracki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305 [PMID: 19721017 DOI: 10.7326/0003-4819-151-5-20090909-00003]
4. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20 [PMID: 19880491 DOI: 10.1182/blood-2009-09-241851]
5. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875 [PMID: 10561769 DOI: 10.1056/NEJM199101173240807]
6. Cannegieter SC, Rosendaal FR, Briët E. Thrombogenic and hemorrhagic complications associated with prosthetic valves.
7. Lengyel M. Management of prosthetic valve thrombosis. J Heart Valve Dis 2004; 13: 329-334 [PMID: 15222767 DOI: 10.1016/S1281-765X(01)90038-0]
8. Taljaard JJ, Doubell AF. Prosthetic valve obstruction at Tygerberg Hospital between January 1991 and February 2001. Cardiovasc J Afr 1992; 14: 182-188 [PMID: 14532959]
9. Piper C, Horstkotte D. State of the art anticoagulation management. J Heart Valve Dis 2004; 13 Suppl 1: S76-S80 [PMID: 15250100]
10. Aoyagi S, Fukunaga S, Suzuki S, Nishi Y, Oryoji A, Kosuga K. Obstruction of mechanical valve prostheses: clinical diagnosis and surgical or nonsurgical management. Surg Today 1996; 26: 400-406 [PMID: 8782297 DOI: 10.1007/BF00311926]
11. Deviri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 1991; 17: 646-650 [PMID: 1993782] DOI: 10.1016/S0735-1097(10)80178-0]
12. Mehra S, Pradudturvar P, Marcu CB, Chelu MG. Use of Novel Oral Anticoagulants Postcardioversion in Atrial Fibrillation: A Safety Review. British J Medicine and Medical Research 2015; 7: 718-722 [DOI: 10.9734/BJMMR/2015/16462]
13. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappestein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khuder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214 [PMID: 23991661 DOI: 10.1056/NEJMoa1300615]
14. Kolominsky-Rabas PL, Weber M, Gefeller O, Neudorfer B,
Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. *Stroke* 2001; 32: 2735-2740 [PMID: 11739965 DOI: 10.1161/hs1201.100209]

15 Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Quiñones MA, Zoghbi WA. Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. *J Am Coll Cardiol* 1998; 32: 1410-1417 [PMID: 9809956 DOI: 10.1016/S0735-1097(98)00385-4]

16 Montorsi P, Cavoretto D, Alimento M, Maratori M, Pepi M. Prosthetic mitral valve thrombosis: can fluoroscopy predict the efficacy of thrombolytic treatment? *Circulation* 2003; 108 Suppl 1: II79-II84 [PMID: 12970213 DOI: 10.1161/01.cir.0000087900.45365.45]

17 Martinell J, Jiménez A, Rábago G, Artiz V, Fraile J, Farré J. Mechanical cardiac valve thrombosis. Is thrombectomy justified? *Circulation* 1991; 84: III70-III75 [PMID: 1934445]

P- Reviewer: Amiri M, Arboix A  S- Editor: Tian YL  L- Editor: A  E- Editor: Liu SQ
